New insights into ovarian cancer pathology

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Prat, J ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Carcinomas; Histopathological types; Molecular genetics; Ovary

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOKERATIN 20; CYTOKERATIN 7; HEPATOCYTE NUCLEAR FACTOR 1BETA; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P53; WT1 PROTEIN;

ARTICLE; AT RICH INTERACTIVE DOMAIN 1A GENE; CANCER GRADING; CANCER MORPHOLOGY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CHEMOSENSITIVITY; CHROMOSOMAL INSTABILITY; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; CYTODIAGNOSIS; DISEASE ASSOCIATION; DOUBLE STRANDED DNA BREAK; ENDOMETRIUM CARCINOMA; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE FUNCTION; GENETIC RISK; HUMAN; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE K RAS; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RECOMBINATION REPAIR;

BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOMA; CHROMOSOMAL INSTABILITY; FEMALE; GERM-LINE MUTATION; HUMANS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY, MOLECULAR;

EID: 84866752100     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds300     Document Type: Article

References (52)

1. Prat J. Pathology of the Ovary. Philadelphia: Saunders 2004.
2. Lee KR, Tavassoli FA, Prat J et al. Surface epithelial-stromal tumours (Ch 2: tumours of the ovary and peritoneum). In Tavassoli FA, Devilee P (eds), World Health Organization classification of tumours: pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press 2003; 117-145.
3. Stewart BW, Kleihues P. World Cancer Report. Lyon: IARC Press, 2003.
4. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 2012; 460: 237-249.
5. Takano M, Kikuchi Y, Yaegashi N et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 2006; 94: 1369-1374.
6. du Bois A, Lück HJ, Meier W et al. A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329.
7. Fountain J, Trimble E, Birrer MJ. Summary and discussion of session recommendations. Gynecol Oncol 2006; 103: S23-S25.
8. Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34: 433-443.
9. Piek JM, van Diest PJ, Zweemer RP et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195: 451-456.
10. Piek JM, van Diest PJ, Zweemer RP et al. Tubal ligation and risk of ovarian cancer. Lancet 2001; 358: 844.
11. Medeiros F, Muto MG, Lee Y et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30: 230-236.
12. Kindelberger DW, Lee Y, Miron A et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-169.
13. Lee Y, Miron A, Drapkin R et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211: 26-35.
14. Folkins AK, Jarboe EA, Saleemuddin A et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008; 109: 168-173.
15. Jarboe E, Folkins A, Nucci MR et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 2008; 27: 1-9.
16. Obata K, Morland SJ, Watson RH et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998; 58: 2095-2097.
17. Sato N, Tsunoda H, Nishida M et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000; 60: 7052-7056.
18. Singer G, Oldt R, III, Cohen Y et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Nat Cancer Inst 2003; 95: 484-486.
19. Singer G, Stöhr R, Cope L et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis. Am J Surg Pathol 2005; 29: 218-224.
20. Malpica A, Deavers MT, Lu K et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004; 28: 496-504.
21. Köbel M, Kalloger SE, Carrick J et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009; 33: 14-21.
22. Risch HA, McLaughlin JR, Cole DE et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J. Natl Cancer Inst 2006; 98: 1694-1706.
23. Venkitaraman AR. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu. Rev Pathol 2009; 4: 461-487.
24. Geisler JP, Hatterman-Zogg MA, Rathe JA et al. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002; 94: 61-67.
25. Esteller M, Silva JM, Dominguez G et al. Promoter hypermethylation is a cause of BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92: 564-569.
26. Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010; 10: 803-808.
27. Pothuri B, Leitao MM, Levine DA et al. Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One 2010; 5: e10358.
28. Norquist BM, Garcia RL, Allison KH et al. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer 2010; 116: 5261-5271.
29. Gershenson DM, Sun CC, Lu KH et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 2006; 108: 361-368.
30. Köbel M, Kalloger SE, Boyd N et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008; 5: e232.
31. Jones S, Wang T-L, Kurman RJ et al. Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 2012; 226: 413-420.
32. Rodriguez IM, Prat J. Mucinous tumors of the ovary. A clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol 2002; 26: 139-152.
33. Lee KR, Scully RE. Mucinous tumors of the ovary. A clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with "pseudomyxomaperitonei". Am J Surg Pathol 2000; 24: 1447-1464.
34. Silverberg SG, Bell DA, Kurman RJ et al. Borderline ovarian tumors: key points and workshop summary. Hum Pathol 2004; 35: 910-917.
35. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM et al. A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer 2006; 94: 904-91353.
36. Cuatrecasas M, Villanueva A, Matias-Guiu X et al. K-ras mutations in mucinous ovarian tumors. A clinicopathologic and molecular study of 95 cases. Cancer 1997; 79: 1581-1586.
37. Park SY, Kim HS, Hong EK et al. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 2002; 33: 1078-1085.
38. Irving JA, Catasús L, Gallardo A et al. Synchronous endometrioid carcinomas of the uterine corpus and ovary: Alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum Pathol 2005; 36: 605-619.
39. Tothill RW, Tinker AV, George J et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-5208.
40. Sainz de la Cuesta R, Eichhorn JH, Rice LW et al. Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 1996; 60: 238-244.
41. Jiang X, Morland SJ, Hitchcock A et al. Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 1998; 58: 1707-1712.
42. Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosisassociated ovarian carcinomas. N Engl J Med 2010; 363: 1532-1543.
43. Palacios J, Gamallo C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998; 58: 1344-1347.
44. Catasús L, Bussaglia E, Rodriguez I et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: Similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 2004; 35: 1360-1368.
45. Gamallo C, Palacios J, Moreno G et al. Beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship withbeta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999; 155: 527-536.
46. Gras E, Catasus L, Argüelles R et al. Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 2001; 92: 2829-2836.
47. Moreno-Bueno G, Gamallo C, Perez-Gallego L et al. Beta-catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 2001; 10: 116-122.
48. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum based chemotherapy. Cancer 2000; 88: 2584-2589.
49. Komiyama S, Aoki D, Tominaga E et al. Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation. Gynecol Oncol 1999; 72: 342-346.
50. Press JZ, De Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8: 17 (Abstract).
51. Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol 2006; 19: 83-89.
52. Kobayashi H, Yamada Y, Kanayama S et al. The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer 2009; 19: 471-479.